This company listing is no longer active
4OD Stock Overview
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Odonate, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.28 |
52 Week High | US$1.46 |
52 Week Low | US$1.08 |
Beta | 0.062 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -95.71% |
5 Year Change | n/a |
Change since IPO | -93.58% |
Recent News & Updates
Recent updates
Shareholder Returns
4OD | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | -1.6% | -0.8% |
1Y | n/a | -29.6% | 1.0% |
Return vs Industry: Insufficient data to determine how 4OD performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 4OD performed against the German Market.
Price Volatility
4OD volatility | |
---|---|
4OD Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 7.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 9.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4OD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4OD's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 145 | Kevin Tang | www.odonate.com |
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Odonate, Inc. Fundamentals Summary
4OD fundamental statistics | |
---|---|
Market cap | €43.79m |
Earnings (TTM) | -€101.27m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 4OD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4OD income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$102.07m |
Earnings | -US$102.07m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | -3.47 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 4OD perform over the long term?
See historical performance and comparison